News | December 24, 2025
Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Marks remarkable acceleration in innovation using AI technology
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The move strengthens GBL’s clinical-stage presence in the United States
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Subscribe To Our Newsletter & Stay Updated
